Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Renata Veselsk"'
Publikováno v:
Cellular & Molecular Biology Letters, Vol 29, Iss 1, Pp 1-47 (2024)
Abstract Prominin-1 (CD133) is a cholesterol-binding membrane glycoprotein selectively associated with highly curved and prominent membrane structures. It is widely recognized as an antigenic marker of stem cells and cancer stem cells and is frequent
Externí odkaz:
https://doaj.org/article/71b271e35210426da4266ab0ab5b0bc8
Autor:
Maria Krchniakova, Silvia Paukovcekova, Petr Chlapek, Jakub Neradil, Jan Skoda, Renata Veselska
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Tyrosine kinase inhibitors (TKIs) are frequently used in combined therapy to enhance treatment efficacy and overcome drug resistance. The present study analyzed the effects of three inhibitors, sunitinib, gefitinib, and lapatinib, combined with iron-
Externí odkaz:
https://doaj.org/article/953b01435918483ea1b53ad2f28c8d72
Autor:
Helena Ramos, Maria I.L. Soares, Joana Silva, Liliana Raimundo, Juliana Calheiros, Célia Gomes, Flávio Reis, Filipe A. Monteiro, Cláudia Nunes, Salette Reis, Bartolomeo Bosco, Silvano Piazza, Lucília Domingues, Petr Chlapek, Petr Vlcek, Pavel Fabian, Ana Teresa Rajado, A.T.P. Carvalho, Renata Veselska, Alberto Inga, Teresa M.V.D. Pinho e Melo, Lucília Saraiva
Publikováno v:
Cell Reports, Vol 35, Iss 2, Pp 108982- (2021)
Summary: Impairment of the p53 pathway is a critical event in cancer. Therefore, reestablishing p53 activity has become one of the most appealing anticancer therapeutic strategies. Here, we disclose the p53-activating anticancer drug (3S)-6,7-bis(hyd
Externí odkaz:
https://doaj.org/article/49516e7fa22e429b9dc9fbabff3cfc73
Autor:
Kristyna Polaskova, Tomas Merta, Alexandra Martincekova, Danica Zapletalova, Michal Kyr, Pavel Mazanek, Zdenka Krenova, Peter Mudry, Marta Jezova, Jiri Tuma, Jarmila Skotakova, Ivana Cervinkova, Dalibor Valik, Lenka Zdrazilova-Dubska, Hana Noskova, Karol Pal, Ondrej Slaby, Pavel Fabian, Sarka Kozakova, Jakub Neradil, Renata Veselska, Veronika Kanderova, Ondrej Hrusak, Tomas Freiberger, Giannoula Lakka Klement, Jaroslav Sterba
Publikováno v:
Frontiers in Oncology, Vol 9 (2020)
In order to identify reasons for treatment failures when using targeted therapies, we have analyzed the comprehensive molecular profiles of three relapsed, poor-prognosis Burkitt lymphoma cases. All three cases had resembling clinical presentation an
Externí odkaz:
https://doaj.org/article/5c281799cb3e41e29ab698bc35a5380e
Autor:
Johannes Gojo, Zdenek Pavelka, Danica Zapletalova, Maria T. Schmook, Lisa Mayr, Sibylle Madlener, Michal Kyr, Klara Vejmelkova, Martin Smrcka, Thomas Czech, Christian Dorfer, Jarmila Skotakova, Amedeo A. Azizi, Monika Chocholous, Dominik Reisinger, David Lastovicka, Dalibor Valik, Christine Haberler, Andreas Peyrl, Hana Noskova, Karol Pál, Marta Jezova, Renata Veselska, Sarka Kozakova, Ondrej Slaby, Irene Slavc, Jaroslav Sterba
Publikováno v:
Frontiers in Oncology, Vol 9 (2020)
Diffuse gliomas with K27M histone mutations (H3K27M glioma) are generally characterized by a fatal prognosis, particularly affecting the pediatric population. Based on the molecular heterogeneity observed in this tumor type, personalized treatment is
Externí odkaz:
https://doaj.org/article/aae136c1580e43fabf033e1522e3cb53
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-13 (2018)
Abstract For decades, retinoids and their synthetic derivatives have been well established anticancer treatments due to their ability to regulate cell growth and induce cell differentiation and apoptosis. Many studies have reported the promising role
Externí odkaz:
https://doaj.org/article/2079bfc87e0544c68564cd815a548ef1
Autor:
Renata Veselska, Marta Jezova, Michal Kyr, Pavel Mazanek, Petr Chlapek, Viera Dobrotkova, Jaroslav Sterba
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
The survival rate for patients with high-risk neuroblastomas remains poor despite new improvements in available therapeutic modalities. A detailed understanding of the mechanisms underlying clinical responses to multimodal treatment is one of the imp
Externí odkaz:
https://doaj.org/article/cc77f362613344c78f1a26281eb21144
Autor:
Jakub Neradil, Michal Kyr, Kristyna Polaskova, Leos Kren, Petra Macigova, Jan Skoda, Jaroslav Sterba, Renata Veselska
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
The specific targeting of signal transduction by low-molecular-weight inhibitors or monoclonal antibodies represents a very promising personalized treatment strategy in pediatric oncology. In this study, we present the successful and clinically relev
Externí odkaz:
https://doaj.org/article/1c0111a9499a459bb2c611ad6acb8995
Autor:
Michal Kyr, Kristyna Polaskova, Zuzana Kuttnerova, Tomas Merta, Jakub Neradil, Jitka Berkovcova, Ondrej Horky, Marta Jezova, Renata Veselska, Giannoula Lakka Klement, Dalibor Valik, Jaroslav Sterba
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Introduction: The individualization of treatment is attractive, especially in children with high-risk cancer. In such a rare and very heterogeneous group of diseases, large population-based clinical randomized trials are not feasible without internat
Externí odkaz:
https://doaj.org/article/86696cb98eda4de6be30002db1ea2e5d
Autor:
Viera Dobrotkova, Petr Chlapek, Marta Jezova, Katerina Adamkova, Pavel Mazanek, Jaroslav Sterba, Renata Veselska
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0218269 (2019)
Although the administration of retinoids represents an important part of treatment for children suffering from high-risk neuroblastomas, approximately 50% of these patients do not respond to this therapy or develop resistance to retinoids during trea
Externí odkaz:
https://doaj.org/article/19d36be6682b4ff194fe653d7664d815